Cost-effectiveness acceptability curves comparing treating all untreated hypertensive adults (blue) with treating only untreated CVD patients and adults with stage 2 hypertension but without CVD (red).

Abstract

<p>The threshold for cost-effective in China assumed for this analysis is labeled at Int$11,900 (China’s GDP per capita; conversion to US dollars from Chinese RMB based on PPP). Twice China’s GDP is also labelled at Int$23,800.</p